Welcome to our dedicated page for Helius Medical Technologies news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Medical Technologies stock.
Helius Medical Technologies, Inc. (symbol: HSDT) is a pioneering neurotechnology company headquartered in Newtown, Pennsylvania, dedicated to developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological diseases or trauma. The company’s flagship product, the Portable Neuromodulation Stimulator (PoNS®), is a novel medical device approved in Canada for the treatment of chronic balance deficits due to mild-to-moderate traumatic brain injury (mTBI) and gait deficits related to multiple sclerosis (MS). The PoNS® device works by delivering gentle electrical stimulation to the tongue's surface, which helps improve balance and gait through enhanced neuromodulation.
Recently, Helius Medical Technologies has achieved significant milestones, including expanding its clinical development program in collaboration with renowned institutions like the Shepherd Center and Brooks Rehabilitation. This expansion aims to further validate PoNS®'s efficacy for treating gait and balance deficits in chronic stroke survivors, highlighting the company’s commitment to broadening therapeutic applications.
In terms of partnerships, Helius has secured a meaningful collaboration with Lovell Government Services to introduce the PoNS® device to the U.S. Department of Veterans Affairs (VA) and other federal healthcare providers. This partnership aims to enhance the quality of life for veterans suffering from MS by providing access to innovative treatments. Real-world studies have shown that PoNS® Therapy can lead to clinically meaningful improvements in gait for all MS patients after 14 weeks of therapy.
Financially, Helius Medical Technologies is focusing on securing widespread reimbursement for the PoNS® device. The company recently received its first third-party reimbursement from a major insurance carrier, a crucial step towards establishing market pricing and expanding access. This follows the Centers for Medicare & Medicaid Services’ (CMS) establishment of unique Healthcare Common Procedure Coding System (HCPCS) codes for the PoNS® components.
Additionally, the PoNS® device is now available for purchase via the VA’s Federal Supply Schedule (FSS) and the GSA Advantage marketplace, ensuring quicker access for veterans and federal employees. The inclusion of PoNS® in these platforms underscores its potential as a game-changing therapy for those affected by neurological conditions, promoting neuroplasticity and improving patients' lives.
For more information about the PoNS® or Helius Medical Technologies, please visit www.heliusmedical.com.
Helius Medical Technologies (NASDAQ: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has announced its participation in the LD Micro Invitational XIII 2023. The event will take place at the Luxe Sunset Boulevard Hotel in California.
President and CEO Dane Andreeff, along with CFO Jeff Mathiesen, will represent Helius at the conference. Their presentation is scheduled for Wednesday, June 7, 2023, at 4:00 PM PT. Interested parties can access the webcast through the provided link.
Investors and attendees wishing to arrange one-on-one meetings with Helius management are encouraged to contact LD Micro directly. This event provides an opportunity for Helius to showcase its innovative approach to neuromodulation therapy and engage with potential investors.
FAQ
What is the current stock price of Helius Medical Technologies (HSDT)?
What is the market cap of Helius Medical Technologies (HSDT)?
What does Helius Medical Technologies, Inc. do?
What is the Portable Neuromodulation Stimulator (PoNS®)?
Where is Helius Medical Technologies headquartered?
What are the recent achievements of Helius Medical Technologies?
How does PoNS® Therapy work?
Is the PoNS® device approved for use in the United States?
What partnerships has Helius Medical Technologies formed?
How is the PoNS® device distributed to veterans?
What is the financial condition of Helius Medical Technologies?